You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

JUNIOR STRENGTH ADVIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Junior Strength Advil, and when can generic versions of Junior Strength Advil launch?

Junior Strength Advil is a drug marketed by Haleon Us Holdings and is included in two NDAs.

The generic ingredient in JUNIOR STRENGTH ADVIL is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-four suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Junior Strength Advil

A generic version of JUNIOR STRENGTH ADVIL was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.

  Sign Up

Summary for JUNIOR STRENGTH ADVIL
Drug patent expirations by year for JUNIOR STRENGTH ADVIL

US Patents and Regulatory Information for JUNIOR STRENGTH ADVIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Haleon Us Holdings JUNIOR STRENGTH ADVIL ibuprofen TABLET, CHEWABLE;ORAL 020944-002 Dec 18, 1998 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Haleon Us Holdings JUNIOR STRENGTH ADVIL ibuprofen TABLET;ORAL 020267-002 Dec 13, 1996 OTC No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for JUNIOR STRENGTH ADVIL

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Rare Diseases Pedea ibuprofen EMEA/H/C/000549
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Authorised no no no 2004-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.